Background: The severity of hemoptysis is usually assessed on the amount of blood expectorated, although no threshold has been agreed upon. Respiratory or hemodynamic failures are additional severity criteria but occur in few cases. Objectives: Early identification of the in-hospital mortality determinants might be helpful to best characterize severe hemoptysis. Methods: This is a retrospective cohort study of consecutive patients with hemoptysis admitted to the ICU of a teaching hospital during a 14-year period. The model for early prediction of in-hospital mortality was developed on a derivation sample (67% of patients) using multiple logistic regression. Calibration and discrimination of the model were tested using the remaining validation sample. A scoring system was developed for clinical use. Results: The in-hospital mortality of the 1,087 patients (age 54 years, 71% male) was 6.5% (95% CI 5–8). Chronic alcoholism, cancer or aspergillosis, pulmonary artery involvement, infiltrates involving two quadrants or more on the admission radiograph, and mechanical ventilation at referral predicted independently mortality. The model showed good concordance between predicted and observed probabilities of death and good discrimination (receiver operating characteristic curve area 0.87; 95% CI 0.82–0.92). The model-based score (chronic alcoholism, pulmonary artery involvement, and radiographic patterns, 1 point each; cancer, aspergillosis, and mechanical ventilation, 2 points each) predicted the probability of death as follows: score 0, 1%; score 1, 2%; score 2, 6%; score 3, 16%; score 4, 34%; score 5, 58%; score 6, 79%, and score 7, 91%. Conclusions: Our results provide useful information about the short-term prognosis of patients with hemoptysis, which could help design therapeutic approaches and management plans according to the risk of in-hospital mortality.

Keywords:
Severe hemoptysis, In-hospital mortality, Scoring, Outcome, Prediction
1.
Ong TH, Eng P: Massive hemoptysis requiring intensive care. Intensive Care Med 2003;29:317–320.
2.
Crocco JA, Rooney JJ, Fankushen DS, DiBenedetto RJ, Lyons HA: Massive hemoptysis. Arch Intern Med 1968;121:495–498.
3.
Dweik RA, Stoller JK: Role of bronchoscopy in massive hemoptysis. Clin Chest Med 1999;20:89–105.
4.
Ibrahim WH: Massive haemoptysis: the definition should be revised. Eur Respir J 2008;32:1131–1132.
5.
Fartoukh M, Khalil A, Louis L, Carette MF, Bazelly B, Cadranel J, Mayaud C, Parrot A: An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral centre. Respir Res 2007;8:11–20.
6.
Mal H, Rullon I, Mellot F, Brugiere O, Sleiman C, Menu Y, Fournier M: Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest 1999;115:996–1001.
7.
Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL: Massive hemoptysis in cystic fibrosis. Chest 2005;128:729–738.
8.
Hirshberg B, Biran I, Glazer M, Kramer MR: Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997;112:440–444.
9.
Coss-Bu JA, Sachdeva RC, Bricker JT, Harrison GM, Jefferson LS: Hemoptysis: a 10-year retrospective study. Pediatrics 1997;100:E7.
10.
Kim YG, Yoon HK, Ko GY, Lim CM, Kim WD, Koh Y: Long-term effect of bronchial artery embolization in Korean patients with haemoptysis. Respirology 2006;11:776–781.
11.
van den Heuvel MM, Els Z, Koegelenberg CF, Naidu KM, Bolliger CT, Diacon AH: Risk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis. Int J Tuberc Lung Dis 2007;11:909–914.
12.
Andrejak C, Parrot A, Bazelly B, Ancel PY, Djibre M, Khalil A, Grunenwald D, Fartoukh M: Surgical lung resection for severe hemoptysis. Ann Thorac Surg 2009;88:1556–1565.
13.
Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753–759.
14.
Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European-North American multicenter study. JAMA 1993;270:2957–2963.
15.
Zubrod CG, Schneiderman M, Frei E 3rd: Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7–33.
16.
Mori H, Ohno Y, Tsuge Y, Kawasaki M, Ito F, Endo J, Funaguchi N, La BL, Kanematsu M, Minatoguchi S: Use of multidetector row CT to evaluate the need for bronchial arterial embolization in hemoptysis patients. Respiration 2010;80:24–31.
17.
Sakr L, Dutau H: Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration 2010;80:38–58.
18.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–1379.
19.
Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989.
20.
Egan JP: Signal Detection Theory and ROC Analysis. New York, Academic Press, 1975.
21.
Amirana M, Frater R, Tirschwell P, Janis M, Bloomberg A, State D: An aggressive surgical approach to significant hemoptysis in patients with pulmonary tuberculosis. Am Rev Respir Dis 1968;97:187–192.
22.
Brinson GM, Noone PG, Mauro MA, Knowles MR, Yankaskas JR, Sandhu JS, Jaques PF: Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998;157:1951–1958.
23.
Corey R, Hla KM: Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci 1987;294:301–309.
24.
Knott-Craig CJ, Oostuizen JD, Rossouw G: Management and prognosis of massive hemoptysis. J Thorac Cardiovascular Surg 1993;105:394–397.
25.
Khalil A, Soussan M, Mangiapan G, Fartoukh M, Parrot A, Carette MF: Utility of high-resolution chest CT scan in the emergency management of haemoptysis in the intensive care unit: severity, localization and aetiology. Br J Radiol 2007;80:21–25.
26.
Lordan JL, Gascoigne A, Corris PA: The pulmonary physician in critical care: illustrative case 7 – assessment and management of massive haemoptysis. Thorax 2003;58:814–819.
27.
Arozullah AM, Daley J, Henderson WG, Khuri SF: Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery: the National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000;232:242–253.
28.
Murphy SA, Mydin HH, Fatah S, Antunes G: Predicting end-of-life in patients with an exacerbation of COPD by routine clinical assessment. Respir Med 2010;104:1668–1674.
29.
Neuenschwander AU, Pedersen JH, Krasnik M, Tønnesen H: Postoperative outcome in chronic alcohol abusers after curative resection for lung cancer. Eur J Cardiothorac Surg 2002;22:287–291.
30.
Roques S, Parrot A, Lavole A, Ancel PY, Gounant V, Djibre M, Fartoukh M: Six-month prognosis of patients with lung cancer admitted to the intensive care unit. Intensive Care Med 2009;35:2044–2050.
31.
Ayed A: Pulmonary resection for massive hemoptysis of benign etiology. Eur J Cardiothorac Surg 2003;24:689–693.
32.
Jougon J, Ballester M, Delcambre F, Bride TM, Valat P, Gomez F, Laurent F, Velly JF: Massive hemoptysis: what place for medical and surgical treatment. Eur J Cardiothorac Surg 2002;22:345–351.
33.
Boussat S, El’rini T, Dubiez A, Depierre A, Barale F, Capellier G: Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med 2000;26:1811–1816.
34.
Ewer MS, Ali MK, Atta MS, Morice RC, Balakrishnan PV: Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure. JAMA 1986;256:3364–3366.
35.
Reichner CA, Thompson JA, O’Brien S, Kuru T, Anderson ED: Outcome and code status of lung cancer patients admitted to the medical ICU. Chest 2006;130:719–723.
36.
Soares M, Darmon M, Salluh JI, Ferreira CG, Thiery G, Schlemmer B, Spector N, Azoulay E: Prognosis of lung cancer patients with life-threatening complications. Chest 2007;131:840–846.
37.
Royston P, Moons KG, Altman DG, Vergouwe Y: Prognosis and prognostic research: developing a prognostic model. BMJ 2009;338:b604.
38.
Altman DG, Vergouwe Y, Royston P, Moons KG: Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338:b605.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.